Glenmark Pharmaceuticals’ arm launches Olopatadine Hydrochloride Ophthalmic Solution

19 Aug 2024 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Therapeutics Inc., USA has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday Twice Daily Relief.

According to Nielsen syndicated data for the latest 52 weeks’ period ending July 13, 2024, the Pataday Twice Daily Relief (OTC) market achieved annual sales of approximately $26.4 million. 

In July, the company had received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Capsules USP, 15 mg and 25 mg.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 

Glenmark Pharma Share Price

1636.05 -2.90 (-0.18%)
03-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.10
Dr. Reddys Lab 1352.75
Cipla 1510.25
Lupin 2367.85
Zydus Lifesciences 975.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.